Louis Kantaros, MD
Interventional Cardiology · Poughkeepsie, NYNPI 1740253798
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,648 of the $65,003 with a category attached, or 85.6%. 21 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 34.5% of the total. Reporting peaked in 2019 at $34,876 and has fallen 99.2% since, to $293 in 2025.
Across 167 payments — averaging $389.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$22K
- Amgen$17K
- Sanofi-aventis U.S. LLC$13K
- Regeneron Healthcare Solutions, Inc.$11K
- Novartis$365
- AstraZeneca$320
- plus $1K from 15 others
Across 101 payments — averaging $6494.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$288K
- Amgen$244K
- AstraZeneca$77K
- Esperion Therapeutics, Inc.$33K
- Bard Peripheral Vascular, Inc.$14K
What the payments were for
- Speaking & faculty fees$55,64886%
- Travel & lodging$5,2238%
- Food & beverage$4,1056%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 18 | $22,441 |
| Amgen | 28 | $16,803 |
| Sanofi-aventis U.S. LLC | 7 | $12,794 |
| Regeneron Healthcare Solutions, Inc. | 26 | $11,091 |
| Novartis | 33 | $365 |
| AstraZeneca | 22 | $320 |
| Abbott | 4 | $275 |
| Bard Peripheral Vascular, Inc. | 3 | $223 |
| Boston Scientific | 4 | $156 |
| Axogen | 1 | $140 |
| Johnson & Johnson | 5 | $88 |
| Philips North America LLC | 1 | $48 |
| Novo Nordisk | 2 | $47 |
| Medtronic(2 entities) | 2 | $39 |
| Boehringer Ingelheim | 3 | $36 |
| Cardiovascular Systems Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| EKOS Corporation | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
| Pfizer | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$23,210
- NEXLIZET$22,382
- NEXLETOL$22,382
- Repatha$16,509
- AVANCE NERVE GRAFT$140
- Mitra Clip system$130
- Venclose Maven Catheter$118
- HeartMate 3 Left Ventricular Dev$102
How this compares
$65,003 in reported general payments places this provider in the 85th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 371 | $502,373 |
| XareltoRivaroxaban | 120 | $168,042 |
| EntrestoSacubitril/Valsartan | 39 | $49,063 |
| Praluent PenAlirocumab | 53 | $37,630 |
| Repatha SureclickEvolocumab | 27 | $32,650 |
| BrilintaTicagrelor | 13 | $15,940 |
| Rosuvastatin Calcium | 593 | $10,707 |
| Atorvastatin Calcium | 711 | $9,059 |
| Metoprolol Succinate | 490 | $9,008 |
| Ezetimibe | 180 | $7,512 |
| Losartan Potassium | 293 | $3,976 |
| Lisinopril | 496 | $3,289 |
| ClopidogrelClopidogrel Bisulfate | 276 | $3,072 |
| Carvedilol | 274 | $2,865 |
| Chlorthalidone | 102 | $2,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $502,373371 claims |
| Johnson & JohnsonXarelto | $88 | $168,042120 claims |
| NovartisEntresto | $365 | $49,06339 claims |
| AstraZenecaBrilinta | $320 | $15,94013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Poughkeepsie
- Rajeev NarayanPoughkeepsie$116K
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.